Autopsy report · NCT01987856

Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a FET Cycle

“loss of funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Antalya IVF

Sponsor type

University, hospital or other

Conditions

Pregnancy

Interventions

Blastocyst morphology

Participants

0

Sites

1

Countries

Turkey (Türkiye)

Trials that died the same way

• Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation
  “Funding loss” (97% match in meaning)
• Meru Health Program to Treat Depression in Primary Care
  “Loss of grant funding.” (89% match in meaning)
• The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
  “Loss of external funding” (87% match in meaning)
• Mepolizumab for Eosinophilic Fasciitis
  “Funding lost from Sponsor.” (86% match in meaning)
• Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
  “Low accrual/Loss of funding” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.